Why the CEO is BIG risk to LABSLarge pharmaceutical companies in the United States are already FDA approved and if they have Canadian subsidiary operations those are approved by Health Canada. In Canada cannabinoids are legal at the Federal level be it pharmaceutical or recreational.
The recent rescheduling of Cannabis in the U.S. from the strickest classification of Schedule 3 (has pharmaceutical applications) vastly changes the landscape for Medipharm Labs.
So to be blunt and frank, who the f""K needs Medipharm Labs? Their DEL for cananbinoids is growing less valuable by the minute.
And you think the CEO has done a good job? Get your ostrich heads out of the sand.